Endocrinology & Diabetes ResearchISSN: 2470-7570

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, Endocrinol Diabetes Res Vol: 2 Issue: 1

A Case Report of Diabetic Ketoacidosis Associated with Multiple Risk Factors Including Dapagliflozin Use

El-rifai M*, Poor D and Khaddash S
Internal Medicine Department, St. Joseph Regional Medical Center, Paterson, USA
Corresponding author : Mohammad El-rifai, MD
Internal Medicine department at St. Joseph Regional Medical Center. 703 Main St, Paterson, NJ 07503, USA
Tel: 973-289-4979
E-mail: [email protected]
Received: January 06, 2016 Accepted: June 07, 2016 Published: June 12, 2016
Citation: El-rifai M, Poor D, Khaddash S (2016) A Case Report of Diabetic Ketoacidosis Associated with Multiple Risk Factors Including Dapagliflozin Use. Endocrinol Diabetes Res 2:1. doi:10.4172/2470-7570.1000114

Abstract

Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of antihyperglycemic agents that inhibit renal glucose reabsorption. This group of medications got more popular in diabetic management as it help to control the blood sugar level and it induce weight loss. However, FDA issued a warning of possible association between SGLT2 inhibitors usage and DKA after the reports of several euglycemic DKA cases associated with the use of SGLT2 inhibitors.

Keywords: Diabetic ketoacidosis; Dapagliflozin; Blood sugar

Track Your Manuscript

Share This Page

Media Partners